Discovery of Potent, Selective Chymase Inhibitors via Fragment Linking Strategies

被引:27
|
作者
Taylor, Steven J. [1 ]
Padyana, Anil K. [1 ]
Abeywardane, Asitha [1 ]
Liang, Shuang [1 ]
Hao, Ming-Hong [6 ]
De Lombaert, Stephane [7 ]
Proudfoot, John [1 ]
Farmer, Bennett S., III [3 ]
Li, Xiang [1 ]
Collins, Brandon [1 ]
Martin, Leslie [4 ]
Albaugh, Daniel R. [1 ]
Hill-Drzewi, Melissa [5 ]
Pullen, Steven S. [2 ]
Takahashi, Hidenori [1 ]
机构
[1] Boehringer Ingelheim Pharmaceut Inc, Dept Med Chem, Ridgefield, CT 06877 USA
[2] Boehringer Ingelheim Pharmaceut Inc, Cardiometab Dis, Ridgefield, CT 06877 USA
[3] Boehringer Ingelheim Pharmaceut Inc, IS Sci Informat Management, Ridgefield, CT 06877 USA
[4] Boehringer Ingelheim Pharmaceut Inc, IS Res Data Acquisit, Ridgefield, CT 06877 USA
[5] Bristol Myers Squibb Co, Lead Evaluat Dept, Wallingford, CT 06492 USA
[6] H3 Biomed, Cambridge, MA 02139 USA
[7] Karos Pharmaceut, New Haven, CT 06511 USA
关键词
MAST-CELLS; PATHOPHYSIOLOGICAL ROLE; MECHANISMS; INFARCTION; FIBROSIS; TARGET;
D O I
10.1021/jm400138z
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Chymase plays an important and diverse role in the homeostasis of a number of cardiovascular processes. Herein, we describe the identification of potent, selective chymase inhibitors, developed using fragment-based, structure-guided linking and optimization techniques. High-concentration biophysical screening methods followed by high-throughput crystallography identified an oxindole fragment bound to the S1 pocket of the protein exhibiting a novel interaction pattern hitherto not observed in chymase inhibitors. X-ray crystallographic structures were used to guide the elaboration/linking of the fragment, ultimately leading to a potent inhibitor that was >100-fold selective over cathepsin G and that mitigated a number of liabilities associated with poor physicochemical properties of the series it was derived from.
引用
收藏
页码:4465 / 4481
页数:17
相关论文
共 50 条
  • [41] The Discovery of Potent and Selective Inhibitors of CYP17 Lyase
    Balog, A.
    Jayaraman, L.
    Fura, A.
    Vite, G. D.
    Gottardis, M.
    Huang, A.
    Newitt, J. A.
    Spires, T. E.
    Obermeier, M. T.
    Beyer, S. M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 38 - 39
  • [42] Discovery of potent, selective dipeptidyl peptidase IV inhibitors.
    Parmee, ER
    He, JF
    Mastracchio, A
    Edmondson, SD
    Xu, JY
    Colwell, LF
    Fisher, MH
    Habulihaz, B
    He, HB
    Leiting, B
    Lyons, KA
    Marsilio, F
    Patel, RA
    Wu, JK
    Wyvratt, MJ
    Thornberry, NA
    Weber, AE
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 228 : U53 - U54
  • [43] Discovery of potent, selective sulfonylfuran urea endothelial lipase inhibitors
    Goodman, Krista B.
    Bury, Michael J.
    Cheung, Mui
    Cichy-Knight, Maria A.
    Dowdell, Sarah E.
    Dunn, Allison K.
    Lee, Dennis
    Lieby, Jeffrey A.
    Moore, Michael L.
    Scherzer, Daryl A.
    Sha, Deyou
    Suarez, Dominic P.
    Murphy, Dennis J.
    Harpel, Mark R.
    Manas, Eric S.
    McNulty, Dean E.
    Annan, Roland S.
    Matico, Rosalie E.
    Schwartz, Benjamin K.
    Trill, John J.
    Sweitzer, Thomas D.
    Wang, Da-Yuan
    Keller, Paul M.
    Krawiec, John A.
    Jaye, Michael C.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (01) : 27 - 30
  • [44] The discovery of novel, potent and selective PDE5 inhibitors
    Bi, YZ
    Stoy, P
    Adam, L
    He, B
    Krupinski, J
    Normandin, D
    Pongrac, R
    Seliger, L
    Watson, A
    Macor, JE
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (18) : 2461 - 2464
  • [45] Discovery of Potent and Selective MNK Kinase Inhibitors for the Treatment of Leukemia
    Vagadia, Purav P.
    Izquierdo-Ferrer, Javier
    Mazewski, Candice
    Blyth, Gavin
    Beauchamp, Elspeth M.
    Clutter, Matthew R.
    Stern, Charlotte L.
    Mishra, Rama K.
    Nahotko, Dominik
    Small, Sara
    Eckerdt, Frank
    Platanias, Leonidas C.
    Schiltz, Gary E.
    JOURNAL OF MEDICINAL CHEMISTRY, 2025, 68 (05) : 5824 - 5844
  • [46] Discovery of Potent and Selective PI3Kγ Inhibitors
    Drew, Samuel L.
    Thomas-Tran, Rhiannon
    Beatty, Joel W.
    Fournier, Jeremy
    Lawson, Kenneth, V
    Miles, Dillon H.
    Mata, Guillaume
    Sharif, Ehesan U.
    Yan, Xuelei
    Mailyan, Artur K.
    Ginn, Elaine
    Chen, Jie
    Wong, Kent
    Soni, Divyank
    Dhanota, Puja
    Chen, Pei-Yu
    Shaqfeh, Stefan G.
    Meleza, Cesar
    Pham, Amber T.
    Chen, Ada
    Zhao, Xiaoning
    Banuelos, Jesus
    Jin, Lixia
    Schindler, Ulrike
    Walters, Matthew J.
    Young, Stephen W.
    Walker, Nigel P.
    Leleti, Manmohan Reddy
    Powers, Jay P.
    Jeffrey, Jenna L.
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (19) : 11235 - 11257
  • [47] Fragment-Linking Approach Using 19F NMR Spectroscopy To Obtain Highly Potent and Selective Inhibitors of β-Secretase
    Jordan, John B.
    Whittington, Douglas A.
    Bartberger, Michael D.
    Sickmier, E. Allen
    Chen, Kui
    Cheng, Yuan
    Judd, Ted
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (08) : 3732 - 3749
  • [48] Fragment-based discovery of potent ERK2 pyrrolopyrazine inhibitors
    Burdick, Daniel J.
    Wang, Shumei
    Heise, Christopher
    Pan, Borlan
    Drummond, Jake
    Yin, JianPing
    Goeser, Lauren
    Magnuson, Steven
    Blaney, Jeff
    Moffat, John
    Wang, Weiru
    Chen, Huifen
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (21) : 4728 - 4732
  • [49] Discovery of Potent and Selective Histone Deacetylase Inhibitors via Focused Combinatorial Libraries of Cyclic α3β-Tetrapeptides
    Olsen, Christian A.
    Ghadiri, M. Reza
    JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (23) : 7836 - 7846
  • [50] Molecular simulation strategies for the discovery of selective inhibitors of β-catenin
    Saranyadevi, S.
    Shanthi, V
    JOURNAL OF THEORETICAL & COMPUTATIONAL CHEMISTRY, 2020, 19 (07):